Acumen Pharmaceuticals (ABOS) Notes Payables (2025 - 2026)

Acumen Pharmaceuticals (ABOS) reported Notes Payables of $14.1 million for Q1 2026, up 61.13% sequentially from $8.8 million in Q4 2025.

Acumen Pharmaceuticals (ABOS) Notes Payables (2025 - 2026) Analysis & Trends

Acumen Pharmaceuticals (ABOS) has 2 years of Notes Payables data on file, last reported at $14.1 million in Q1 2026.

For the quarter ending Q1 2026, Notes Payables changed N/A year-over-year to $14.1 million; the trailing twelve-month figure through Mar 2026 stood at $14.1 million (changed N/A YoY), and the FY2025 full-year result was $8.8 million, changed N/A from the prior year.
Notes Payables grew to $14.1 million in Q1 2026, from $8.8 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $14.1 million in Q1 2026 to a low of $3.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Acumen Pharmaceuticals	140.98 Mn	140.98 Mn	-

Download Data